GlassScriptPhysician profile
Matthew Charles Smith
NPI 1104323542
$4,640.69
in general payments reported to CMS, 2019-2025
30 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $158 · 2021: $1,143 · 2022: $1,157 · 2023: $489 · 2024: $905 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.20 |
| Education | $144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $634.05 | 2022-2025 | Wakix |
| Emd Serono, INC. | $555.02 | 2020-2025 | Mavenclad |
| Abbvie INC. | $525.08 | 2020-2024 | Botox |
| Alexion Pharmaceuticals, INC. | $338.58 | 2019-2025 | Ultomiris |
| Boston Scientific Corporation | $311.64 | 2022-2024 | Lithoclast, Ams 700, Rezum Generator |
| Biogen, INC. | $273.92 | 2019-2021 | |
| Genentech USA, INC. | $260.17 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $238.67 | 2022 | |
| Inspire Medical Systems, INC. | $194.18 | 2024-2025 | Inspire |
| Biohaven Pharmaceuticals, INC. | $183.26 | 2021 | |
| Amneal Pharmaceuticals LLC | $164.96 | 2019-2022 | |
| Acorda Therapeutics, INC | $151.74 | 2019-2021 | |
| Lundbeck LLC | $131.15 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $121.83 | 2022 | |
| Genzyme Corporation | $118.71 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.56 | 2021 | |
| Adamas Pharmaceuticals, INC. | $52.82 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $45.58 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.51 | 2022 | |
| Lilly USA, LLC | $27.84 | 2022 | |
| Ucb, INC. | $24.51 | 2021 | |
| Eisai INC. | $24.13 | 2022 | |
| Horizon Therapeutics Plc | $22.66 | 2022 | |
| Medtronic, INC. | $20.51 | 2022 | |
| Gilead Sciences, INC. | $18.55 | 2022 | |
| Mdd US Operations, LLC | $17.49 | 2021 | |
| Octapharma USA, INC. | $17.35 | 2022 | |
| Csl Behring | $13.17 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.17 | 2022 | |
| Vertical Pharmaceuticals, LLC | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.